Syndax Pharmaceuticals, Inc.
NASDAQSyndax Pharmaceuticals arrives at its May 5 investor event carrying fresh wounds — a Q1 revenue miss, an 11% single-day drop, and short interest at 24% of the free float. Short sellers are deeply dug in. At 24.1% of the float — held roughly flat over the past month — the bear position is one of the more substantial in the biotech universe. Yet the lending market tells a calmer…
Snapshot as of 7 May 2026
Syndax Pharmaceuticals arrives at its May 5 investor event carrying fresh wounds — a Q1 revenue miss, an 11% single-day drop, and short interest at 24% of the free float. Short sellers are deeply dug in. At 24.1% of…
Syndax Pharmaceuticals reports Q1 2026 results after market close today, entering the print with its stock down 6.6% on the week and 12% over the past month — back to prices last seen before a brief rally this spring.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SNDX — free to start on ORTEX.
Sign up for free →Open SNDX on ORTEX